Novartis RNA drug acquired in $12B Avidity deal notches a trial win

The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.

By Gwendolyn Wu • June 11, 2026

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy. 

By Jonathan Gardner • June 11, 2026

Explore the Trendline➔

Oncology's research boom

More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.

By BioPharma Dive staff

Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

By Delilah Alvarado • June 9, 2026

Tango data add to growing momentum for pancreatic cancer drugs

A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.

By Jonathan Gardner • June 8, 2026

ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

By Ben Fidler • June 8, 2026

Study data convince Lundbeck to push new migraine drug forward

A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.

By Jacob Bell • June 5, 2026

An ADC specialist sinks on safety concerns for blood cancer drug

Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”

By Delilah Alvarado • June 4, 2026

Legend surges on early data for ‘in vivo’ lymphoma cell therapy

Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.

By Jonathan Gardner • June 3, 2026

Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial

Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.

By Delilah Alvarado • June 2, 2026

AbiVax falls as safety worries cloud ‘landmark’ immune drug results

A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.

By Ben Fidler • June 2, 2026

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

By Jonathan Gardner , Delilah Alvarado • June 2, 2026

Akeso, Summit drug extends survival in closely watched lung cancer trial

Though ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.

By Jonathan Gardner • Updated June 1, 2026

‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.

By Jonathan Gardner • May 31, 2026

At ASCO, Merck makes case for a ‘cornerstone’ cancer drug

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.

By Delilah Alvarado • May 29, 2026

Bristol Myers unveils data for one of its next-gen blood cancer drugs

Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.

By Jonathan Gardner • May 29, 2026

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

By Jonathan Gardner • May 28, 2026

Kailera’s three-pronged obesity shot shows promise in early trial

As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.

By Jonathan Gardner • May 27, 2026

Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

By Jonathan Gardner • May 26, 2026

Measuring what matters: New priorities in COA selection

Detecting meaningful change in rare disease trials requires more than statistics—it demands the right COA. Discover why sensitivity matters and how AI is transforming trial outcomes.

May 26, 2026

ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting

Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, BioNTech, Eli Lilly and Moderna.

By BioPharma Dive staff • May 22, 2026

Parkinson’s drug from Biogen, Denali comes up short

High-level results have led the companies to scrap a mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.

By Jacob Bell • Updated May 22, 2026

BioMarin notches win in study that could expand use of top-selling medicine

The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition.

By Kristin Jensen • May 21, 2026

Lilly’s triple-acting obesity drug hits goal in Phase 3 trial

Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.

By Jonathan Gardner • May 21, 2026

BioMarin drug acquired in buyout misses goal in rare disease study

Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects. 

By Delilah Alvarado • May 19, 2026

Relay drug shows early promise against rare blood vessel diseases

While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.

By Ben Fidler • May 19, 2026